Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study-Reference-Cited by-同舟云学术

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

Published:2013-06 Issue:9883 Volume:381 Page:2091-2099
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy;Humphreys;Cochrane Database Syst Rev,2010

2. Antiretroviral roll-out: the problem of second-line therapy;Boyd;Lancet,2009

3. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227;Ruxrungtham;HIV Med,2008

4. Lopinvair/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings;Bartlett;AIDS,2012

5. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study;Bunupuradah;Antivir Ther,2012

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes;Open Forum Infectious Diseases;2023-10-31

2. Brief Report: Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion;JAIDS Journal of Acquired Immune Deficiency Syndromes;2023-10-01

3. Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings;Diagnostics;2023-06-29

4. We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy;The Lancet HIV;2023-03

5. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12